Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

医学 替莫唑胺 内科学 佐剂 临床研究阶段 临床终点 不利影响 生存素 外科 肿瘤科 化疗 临床试验 无进展生存期 放射治疗 胃肠病学 癌症
作者
Manmeet S. Ahluwalia,David A. Reardon,Ajay Abad,William T. Curry,Eric T. Wong,Sheila Figel,Laszlo Mechtler,David M. Peereboom,Alan D. Hutson,Henry Withers,Song Liu,Ahmed Belal,Jingxin Qiu,Kathleen Mogensen,Sanam Dharma,Andrew Dhawan,Meaghan Birkemeier,Danielle Casucci,Michael J. Ciesielski,Robert A. Fenstermaker
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:41 (7): 1453-1465 被引量:57
标识
DOI:10.1200/jco.22.00996
摘要

PURPOSE Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high. SurVaxM is a peptide vaccine conjugate that has been shown to activate the immune system against its target molecule survivin, which is highly expressed by glioblastoma cells. We conducted a phase IIa, open-label, multicenter trial evaluating the safety, immunologic effects, and survival of patients with nGBM receiving SurVaxM plus adjuvant TMZ following surgery and chemoradiation (ClinicalTrials.gov identifier: NCT02455557 ). METHODS Sixty-four patients with resected nGBM were enrolled including 38 men and 26 women, in the age range of 20-82 years. Following craniotomy and fractionated radiation therapy with concurrent TMZ, patients received four doses of SurVaxM (500 μg once every 2 weeks) in Montanide ISA-51 plus sargramostim (granulocyte macrophage colony-stimulating factor) subcutaneously. Patients subsequently received adjuvant TMZ and maintenance SurVaxM concurrently until progression. Progression-free survival (PFS) and overall survival (OS) were reported. Immunologic responses to SurVaxM were assessed. RESULTS SurVaxM plus TMZ was well tolerated with no serious adverse events attributable to SurVaxM. Of the 63 patients who were evaluable for outcome, 60 (95.2%) remained progression-free 6 months after diagnosis (prespecified primary end point). Median PFS was 11.4 months and median OS was 25.9 months measured from first dose of SurVaxM. SurVaxM produced survivin-specific CD8+ T cells and antibody/immunoglobulin G titers. Apparent clinical benefit of SurVaxM was observed in both methylated and unmethylated patients. CONCLUSION SurVaxM appeared to be safe and well tolerated. The combination represents a promising therapy for nGBM. For patients with nGBM treated in this manner, PFS may be an acceptable surrogate for OS. A large randomized clinical trial of SurVaxM for nGBM is in progress.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
感动的笑翠完成签到,获得积分10
刚刚
jacob258发布了新的文献求助10
1秒前
留胡子的小甜瓜完成签到,获得积分20
1秒前
3秒前
zzq778完成签到,获得积分10
3秒前
spy发布了新的文献求助10
3秒前
齐半青完成签到,获得积分10
5秒前
Sophia完成签到,获得积分10
5秒前
上杉绘梨衣完成签到,获得积分10
6秒前
6秒前
6秒前
干净问筠完成签到,获得积分10
7秒前
大模型应助雷总采纳,获得10
7秒前
美丽松鼠发布了新的文献求助10
8秒前
积极南珍完成签到,获得积分20
9秒前
丘比特应助MXX采纳,获得10
10秒前
烟花应助zzq778采纳,获得10
10秒前
iwsaml发布了新的文献求助10
10秒前
说不得大师完成签到,获得积分10
13秒前
zeng完成签到,获得积分10
14秒前
hmx应助邓谷云采纳,获得10
14秒前
14秒前
TING完成签到 ,获得积分10
16秒前
123完成签到,获得积分10
17秒前
orixero应助美丽松鼠采纳,获得10
17秒前
19秒前
19秒前
钱财实景完成签到,获得积分10
20秒前
zhao完成签到,获得积分10
20秒前
21秒前
joysa完成签到,获得积分10
21秒前
DddZS完成签到 ,获得积分10
22秒前
阔达的无剑应助wllllll采纳,获得20
22秒前
23秒前
zino完成签到,获得积分10
23秒前
long完成签到,获得积分10
24秒前
24秒前
laity完成签到,获得积分10
24秒前
zzq778发布了新的文献求助10
25秒前
大樗发布了新的文献求助10
26秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3162623
求助须知:如何正确求助?哪些是违规求助? 2813541
关于积分的说明 7900768
捐赠科研通 2473078
什么是DOI,文献DOI怎么找? 1316652
科研通“疑难数据库(出版商)”最低求助积分说明 631468
版权声明 602175